The Key to Policy Change

June 30, 2017
Mark McClellan, MD, PhD

Health Evolution's David Brailer (also a member of the Duke-Margolis Advisory Board) sat down with director Mark McClellan to discuss the next iteration of the value equation to include prescription drugs, devices and gene therapies.

Watch the Video

David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.

The Key to Policy Change

David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.

The Key to Policy Change

David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.